Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people

Endocrine Journal

Volumn 59, Issue 10, 2012, Pages 949-953

  Kirino, Yasushi ^a   Sei, Masako ^a   Kawazoe, Kazuyoshi ^a   Minakuchi, Kazuo ^a   Sato, Youichi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Adiponectin; Body mass index (BMI); Dipeptidyl peptidase 4 (DPP4) activity; Healthy young subject

Indexed keywords

ADIPONECTIN; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; BODY FAT; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; NOTE; OBESITY; PROTEIN BLOOD LEVEL; STUDENT;

ADIPONECTIN; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; FEMALE; HUMANS; MALE; OBESITY; TRIGLYCERIDES; YOUNG ADULT;

EID: 84869225498     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0158     Document Type: Note

References (22)

1. Kos K, Backer AR, Jernas M, Harte AL, Clapham JC, et al. (2009) DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 11: 285-292.
2. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9-24.
3. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, et al. (2009) Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 623: 148-154.
4. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, et al. (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52: 741-750
5. Larsen PJ (2008) Mechanisms behind GLP-1 induced weight loss. Br J Diabetes Vasc Dis 8: S34-S41.
6. Kirino Y, Kamimoto T, Sato Y, Kawazoe K, Minakuchi K, et al. (2009) Increased plasma dipeptidyl peptidase IV (DPP4) activity and decreased DPP4 activity of visceral but not subcutaneous adipose tissue in impaired glucose tolerance rats induced by high-fat or high-sucrose diet. Biol Pharm Bull 32: 463-467.
7. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K (2011) Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab 300: E372-379.
8. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, et al. (2009) Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 200: 53-61.
9. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, et al. (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48: 1168-1172.
10. Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, et al. (2006) Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 155:485-493.
11. McKillop AM, Duffy NA, Lindsay JR, O'Harte FP, Bell PM, et al. (2008) Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36) amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 79: 79-85.
12. Meneilly GS, Demuth HU, McIntosh CHS, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346-350
13. Korosi J, Mcintosh CHS, Pederson RA, Demuth HU, Habener JF, et al. (2001) Effect of aging and diabetes on the enteroinsular axis. J Gerontol Biol Sci Med Sci 56: M575-579.
14. Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, et al. (2004) Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36:111-115.
15. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, et al. (2011) Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60:1917-1925.
16. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A (2012) The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformintreated patients. Diabetes Obes Metab 14:518-522.
17. Sakamoto K, Sato Y, Shinka T, Sei M, Nomura I, et al. (2009) Proteasome subunits mRNA expressions correlate with male BMI: implications for a role in obesity. Obesity (Silver Spring) 17:1044-1049.
18. Hirose H, Yamamoto Y, Seino-Yoshihara Y, Kawabe H, Saito I (2010) Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb 17:1201-1211.
19. Medina-Bravo P, Meza-Santibáñez R, Rosas-Fernández P, Galván-Duarte R, Saucedo-García R, et al. (2011) Decrease in serum adiponectin levels associated with visceral fat accumulation independent of pubertal stage in children and adolescents. Arch Med Res 42:115-121.
20. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, et al. (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28-31.
21. Pala L, Ciani S, Dicembrini I, Bardini G, Cresci A, et al. (2010) Relationship between LP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. Diabet Med 27:691-695.
22. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439-451.